Related references
Note: Only part of the references are listed.Mechanisms of Resistance to Antibody-Drug Conjugates
Rita Khoury et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)
Ado-tratuzumab emtansine beyond breast cancer: therapeutic role of targeting other HER2-positive cancers
Yang Zheng et al.
FRONTIERS IN MOLECULAR BIOSCIENCES (2023)
Cellular therapy in lymphoma
Anna Sureda et al.
HEMATOLOGICAL ONCOLOGY (2023)
FDA Approval Summary: Margetuximab plus Chemotherapy for Advanced or Metastatic HER2-Positive Breast Cancer
Melanie Royce et al.
CLINICAL CANCER RESEARCH (2022)
Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements
Alison M. Schram et al.
CANCER DISCOVERY (2022)
Bispecific antibody simultaneously targeting PD1 and HER2 inhibits tumor growth via direct tumor cell killing in combination with PD1/PDL1 blockade and HER2 inhibition
Chang-ling Gu et al.
ACTA PHARMACOLOGICA SINICA (2022)
Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer
Bob T. Li et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Development of Monoclonal Antibody 281-mG2a-f Against Golden Hamster Podoplanin
Ren Nanamiya et al.
Monoclonal Antibodies in Immunodiagnosis and Immunotherapy (2022)
Improved anti-solid tumor response by humanized anti-podoplanin chimeric antigen receptor transduced human cytotoxic T cells in an animal model
Akihiro Ishikawa et al.
GENES TO CELLS (2022)
Resistance to Trastuzumab
Sneha Vivekanandhan et al.
CANCERS (2022)
Development of a Novel Anti-HER2 Monoclonal Antibody H2Mab-181 for Gastric Cancer
Junko Takei et al.
Monoclonal Antibodies in Immunodiagnosis and Immunotherapy (2021)
An Anti-HER2 Monoclonal Antibody H2Mab-41 Exerts Antitumor Activities in Mouse Xenograft Model Using Dog HER2-Overexpressed Cells
Nami Tateyama et al.
Monoclonal Antibodies in Immunodiagnosis and Immunotherapy (2021)
Targeting ADCC: A different approach to HER2 breast cancer in the immunotherapy era
Pablo Mando et al.
BREAST (2021)
A bispecific antibody targeting HER2 and PD-L1 inhibits tumor growth with superior efficacy
Yi-Li Chen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2021)
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer A Phase 3 Randomized Clinical Trial
Hope S. Rugo et al.
JAMA ONCOLOGY (2021)
A cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity
Morgane Boulch et al.
SCIENCE IMMUNOLOGY (2021)
Mechanisms of Therapeutic Antitumor Monoclonal Antibodies
Li-Chung Tsao et al.
CANCER RESEARCH (2021)
Overcoming trastuzumab resistance in HER2-positive breast cancer using combination therapy
Afshin Derakhshani et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2020)
H2Mab-19, an anti-human epidermal growth factor receptor 2 monoclonal antibody exerts antitumor activity in mouse oral cancer xenografts
Junko Takei et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2020)
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
Kohei Shitara et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Targeting the Human Epidermal Growth Factor Receptor Family in Breast Cancer beyond HER2
Kerstin Riecke et al.
BREAST CARE (2020)
The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy
Takashi Nakada et al.
CHEMICAL & PHARMACEUTICAL BULLETIN (2019)
HER2 and Breast Cancer - A Phenomenal Success Story
Daniel F. Hayes
NEW ENGLAND JOURNAL OF MEDICINE (2019)
FDA approves first CAR T therapy
Asher Mullard
NATURE REVIEWS DRUG DISCOVERY (2017)
A phase I trial of the trifunctional anti Her2 x anti CD3 antibody ertumaxomab in patients with advanced solid tumors
N. Haense et al.
BMC CANCER (2016)
Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity
Yusuke Ogitani et al.
CANCER SCIENCE (2016)
Current challenges in HER2-positive breast cancer
Fabio Puglisi et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
CAR T Cells Targeting Podoplanin Reduce Orthotopic Glioblastomas in Mouse Brains
Satoshi Shiina et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Evaluation of IDH1 status in diffusely infiltrating gliomas by immunohistochemistry using anti-mutant and wild type IDH1 antibodies
Hayato Ikota et al.
BRAIN TUMOR PATHOLOGY (2015)
Trastuzumab Triggers Phagocytic Killing of High HER2 Cancer Cells In Vitro and In Vivo by Interaction with Fcγ Receptors on Macrophages
Yun Shi et al.
JOURNAL OF IMMUNOLOGY (2015)
Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas
Yukinari Kato
BRAIN TUMOR PATHOLOGY (2015)
Combination of novel HER2-targeting antibody 1E11 with trastuzumab shows synergistic antitumor activity in HER2-positive gastric cancer
Bong-Kook Ko et al.
MOLECULAR ONCOLOGY (2015)
ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
Carlos L. Arteaga et al.
CANCER CELL (2014)
First FDA Approval of Neoadjuvant Therapy for Breast Cancer: Pertuzumab for the Treatment of Patients with HER2-Positive Breast Cancer
Laleh Amiri-Kordestani et al.
CLINICAL CANCER RESEARCH (2014)
FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer
Laleh Amiri-Kordestani et al.
CLINICAL CANCER RESEARCH (2014)
A FcγRIII-engaging bispecific antibody expands the range of HER2-expressing breast tumors eligible to antibody therapy
Marc Turini et al.
ONCOTARGET (2014)
HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer
Nadia Harbeck et al.
BREAST CARE (2013)
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
Sandra M. Swain et al.
LANCET ONCOLOGY (2013)
Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3
Charlotte F. McDonagh et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Trifunctional antibody ertumaxomab Non-immunological effects on Her2 receptor activity and downstream signaling
Simone Diermeier-Daucher et al.
MABS (2012)
Highly Sensitive Detection of HER2 Extracellular Domain in the Serum of Breast Cancer Patients by Piezoelectric Microcantilevers
LiNa Loo et al.
ANALYTICAL CHEMISTRY (2011)
Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer
Teemu T. Junttila et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties
Jeffrey L. Nordstrom et al.
BREAST CANCER RESEARCH (2011)
Increased mortality in HER2 positive, oestrogen receptor positive invasive breast cancer: a population-based study
C. A. Purdie et al.
BRITISH JOURNAL OF CANCER (2010)
Population-based Estimate of the Prevalence of HER-2 Positive Breast Cancer Tumors for Early Stage Patients in the US
Kathleen A. Cronin et al.
CANCER INVESTIGATION (2010)
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer
V. Guarneri et al.
CANCER TREATMENT REVIEWS (2010)
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine
Jeffrey S. Ross et al.
ONCOLOGIST (2009)
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
Gail D. Lewis Phillips et al.
CANCER RESEARCH (2008)
Drug therapy: Trastuzumab - Mechanism of action and use in clinical practice
Clifford A. Hudis
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer
G. Valabrega et al.
ANNALS OF ONCOLOGY (2007)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
MC Franklin et al.
CANCER CELL (2004)
HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice
D Finkle et al.
CLINICAL CANCER RESEARCH (2004)
Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma
DM Abd El-Rehim et al.
BRITISH JOURNAL OF CANCER (2004)
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
HS Cho et al.
NATURE (2003)
The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors
TPJ Garrett et al.
MOLECULAR CELL (2003)
The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity
T Shinkawa et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
DB Agus et al.
CANCER CELL (2002)
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
CL Vogel et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
RA Clynes et al.
NATURE MEDICINE (2000)
Share Paper
